These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35349533)

  • 21. End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients.
    Ahn J; Bhuket T; Mosadeghi S; Frenette C; Liu B; Wong RJ
    Hepatol Int; 2016 Sep; 10(5):838-46. PubMed ID: 27221700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethnicity and Insurance-Specific Disparities in the Model for End-Stage Liver Disease Score at Time of Liver Transplant Waitlist Registration and its Impact on Mortality.
    Robinson A; Hirode G; Wong RJ
    J Clin Exp Hepatol; 2021; 11(2):188-194. PubMed ID: 33746443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The decreasing predictive power of MELD in an era of changing etiology of liver disease.
    Godfrey EL; Malik TH; Lai JC; Mindikoglu AL; Galván NTN; Cotton RT; O'Mahony CA; Goss JA; Rana A
    Am J Transplant; 2019 Dec; 19(12):3299-3307. PubMed ID: 31394020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Waitlist mortality in patients with autoimmune liver diseases.
    Goyes D; Barba R; Medina-Morales E; Saberi B; Patwardhan V; Bonder A
    Ann Hepatol; 2022; 27(6):100742. PubMed ID: 35835366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Underestimation of Liver Transplantation for Alcoholic Hepatitis in the National Transplant Database.
    Lee BP; Im GY; Rice JP; Weinberg E; Hsu C; Fix OK; Therapondos G; Han H; Victor DW; Eswaran S; Maddur H; Terrault NA
    Liver Transpl; 2019 May; 25(5):706-711. PubMed ID: 30882995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis.
    Musto J; Stanfield D; Ley D; Lucey MR; Eickhoff J; Rice JP
    Hepatology; 2022 Jan; 75(1):104-114. PubMed ID: 34387875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis.
    Trépo E; Goossens N; Fujiwara N; Song WM; Colaprico A; Marot A; Spahr L; Demetter P; Sempoux C; Im GY; Saldarriaga J; Gustot T; Devière J; Thung SN; Minsart C; Sersté T; Bontempi G; Abdelrahman K; Henrion J; Degré D; Lucidi V; Rubbia-Brandt L; Nair VD; Moreno C; Deltenre P; Hoshida Y; Franchimont D
    Gastroenterology; 2018 Mar; 154(4):965-975. PubMed ID: 29158192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with severe acute-on-chronic liver failure are disadvantaged by model for end-stage liver disease-based organ allocation policy.
    Sundaram V; Shah P; Mahmud N; Lindenmeyer CC; Klein AS; Wong RJ; Karvellas CJ; K Asrani S; Jalan R
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1204-1213. PubMed ID: 32725664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELD-Na allocation.
    Zhou K; Dodge JL; Xu E; Emamaullee J; Kahn JA
    Clin Transplant; 2022 Feb; 36(2):e14527. PubMed ID: 34731515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
    J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model for end-stage liver disease underestimates mortality of patients with acute-on-chronic liver failure waiting for liver transplantation.
    Chang J; Matheja A; Krzycki S; Lutz P; Böhling N; Glückert K; Weismüller TJ; van Beekum C; Manekeller S; Jansen C; Kalff JC; Strassburg CP; Praktiknjo M
    Dig Liver Dis; 2022 Jun; 54(6):784-790. PubMed ID: 34996730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Korean Liver Allocation System using Model for End Stage Liver Disease Scores: A Nationwide, Multicenter study.
    Lee J; Lee JG; Jung I; Joo DJ; Kim SI; Kim MS;
    Sci Rep; 2019 May; 9(1):7495. PubMed ID: 31097768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index.
    Biggins SW; Gralla J; Dodge JL; Bambha KM; Tong S; Barón AE; Inadomi J; Terrault N; Rosen HR
    Am J Transplant; 2014 Nov; 14(11):2588-94. PubMed ID: 25243648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of an Integrated Transplantation Mental Health Program on Alcohol Relapse After Liver Transplantation for Severe Alcoholic Hepatitis: A Single-Center Prospective Study.
    Zanowski SC; Price JS; Selim MA; Schumann V; Durazo F; Hong JC
    Transplant Proc; 2022 Dec; 54(10):2627-2633. PubMed ID: 36411097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of a Prohibitive Versus Restrictive Tobacco Policy on Liver Transplant Candidate Outcomes.
    Likhitsup A; Hassan A; Mellinger J; Askari F; Winder GS; Saeed N; Sonnenday CJ; Sharma P; Fontana RJ
    Liver Transpl; 2019 Aug; 25(8):1165-1176. PubMed ID: 31116906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Model for end-stage liver disease score versus Maddrey discriminant function score in assessing short-term outcome in alcoholic hepatitis.
    Kadian M; Kakkar R; Dhar M; Kaushik RM
    J Gastroenterol Hepatol; 2014 Mar; 29(3):581-8. PubMed ID: 24117536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.